Jazz Pharmaceuticals Plc (JAZZ)
243.78
-6.90
(-2.75%)
USD |
NASDAQ |
Sep 01, 12:01
Jazz Pharmaceuticals Cash from Operations (TTM) : 1.661B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.661B |
| March 31, 2026 | 1.334B |
| December 31, 2025 | 1.356B |
| September 30, 2025 | 1.392B |
| June 30, 2025 | 1.316B |
| March 31, 2025 | 1.558B |
| December 31, 2024 | 1.396B |
| September 30, 2024 | 1.165B |
| June 30, 2024 | 1.073B |
| March 31, 2024 | 1.039B |
| December 31, 2023 | 1.092B |
| September 30, 2023 | 1.267B |
| June 30, 2023 | 1.377B |
| March 31, 2023 | 1.384B |
| December 31, 2022 | 1.272B |
| September 30, 2022 | 1.108B |
| June 30, 2022 | 963.83M |
| March 31, 2022 | 702.49M |
| December 31, 2021 | 778.51M |
| September 30, 2021 | 787.02M |
| June 30, 2021 | 770.85M |
| March 31, 2021 | 911.68M |
| December 31, 2020 | 899.65M |
| September 30, 2020 | 801.18M |
| June 30, 2020 | 880.79M |
| Date | Value |
|---|---|
| March 31, 2020 | 847.12M |
| December 31, 2019 | 776.40M |
| September 30, 2019 | 912.95M |
| June 30, 2019 | 796.02M |
| March 31, 2019 | 832.39M |
| December 31, 2018 | 792.50M |
| September 30, 2018 | 772.71M |
| June 30, 2018 | 741.03M |
| March 31, 2018 | 690.91M |
| December 31, 2017 | 693.09M |
| September 30, 2017 | 667.37M |
| June 30, 2017 | 611.50M |
| March 31, 2017 | 603.42M |
| December 31, 2016 | 590.54M |
| September 30, 2016 | 531.44M |
| June 30, 2016 | 573.48M |
| March 31, 2016 | 587.04M |
| December 31, 2015 | 531.94M |
| September 30, 2015 | 544.62M |
| June 30, 2015 | 499.24M |
| March 31, 2015 | 433.60M |
| December 31, 2014 | 405.76M |
| September 30, 2014 | 352.55M |
| June 30, 2014 | 352.65M |
| March 31, 2014 | 286.45M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Avadel Pharmaceuticals Plc | 37.01M |
| Perrigo Co. Plc | 196.10M |
| GH Research Plc | -52.32M |
| Cosmo NV | -23.86M |
| Axsome Therapeutics, Inc. | -71.26M |